Nigeria Ebola case, Ultomiris kidney-disease approval and WHO TB diagnostic evidence guidance.
Nigeria confirmed its first Ebola case since 2014, involving a traveller who arrived in Abuja via Uganda and Ethiopia. Authorities identified 44 contacts, mostly healthcare workers, and placed the patient in isolation for treatment.
Why it matters: The outbreak’s expansion to another African region reinforces the importance of travel-history assessment, timely testing and infection prevention.
Read at Reuters →AstraZeneca announced accelerated FDA approval of Ultomiris for adults with IgA nephropathy. An interim trial analysis showed a 43.4% reduction in urine protein versus placebo at 34 weeks; continued follow-up will assess whether treatment slows kidney-function decline.
Why it matters: Adds a treatment option while longer-term kidney outcomes remain under evaluation for traditional approval.
Read at Reuters →WHO published its first guidance specifically addressing evidence generation for new TB diagnostics, sample types and testing strategies. It covers study design and diagnostic accuracy alongside patient outcomes, cost-effectiveness, equity and implementation feasibility.
Why it matters: Gives developers, researchers and funders a clearer framework for studies that can support WHO recommendations and adoption in national programmes.
Read at WHO →Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.